Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Earl Darby

Gastroenterology Oakland, CA Medical Doctor

NPI 1790743292 CMS profile 35502

300 Frank H Ogawa Plz, Suite 450, Oakland, CA 94612

Open in the dashboard

General payments

$3,486

195 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Earl Darby of Oakland, CA is reported in the CMS Open Payments database as having received $3,486 across 195 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $19 1
2021 General $881 48
2020 General $1,109 45
2019 General $1,477 101

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Earl Darby
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Earl Darby were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Earl Darby Gastroenterology median Middle half National median
2019 $1,477 $417 $126–$1,100 $163
2020 $1,109 $224 $74–$624 $114
2021 $881 $352 $106–$1,054 $132
2022 $19 $448 $129–$1,270 $149
2023 $0 $533 $150–$1,390 $160
2024 $0 $605 $160–$1,606 $164
2025 $0 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. AbbVie, Inc. $844 45 payments
  2. Gilead Sciences, Inc. $626 39 payments
  3. Janssen Biotech, Inc. $488 29 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $359 25 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $197 12 payments
  6. Daiichi Sankyo Inc. $175 8 payments
  7. Shionogi Inc $116 4 payments
  8. Cook Medical LLC $110 1 payment
  9. Pfizer Inc. $90 5 payments
  10. Braintree Laboratories, Inc. $70 4 payments
  11. Other $409 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $3,486 195 payments
Products named General payments · program years 2019–2022
  1. STELARA $488 29 payments
  2. HUMIRA $382 18 payments
  3. CREON $290 17 payments
  4. ENTYVIO $142 7 payments
  5. MAVYRET $133 8 payments
  6. XIFAXAN $132 9 payments
  7. INJECTAFER $120 5 payments
  8. Mulpleta $116 4 payments
  9. Vemlidy $114 1 payment
  10. LINZESS $111 6 payments
  11. Other $1,237 67 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

195 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record